Search

everythinglearnresearchcommunity

for

Search:↓

Etanercept, a psoriasis treatment, caused hair loss in a patient.

Treatment with biologic agents can significantly improve psoriasis symptoms, and blood biomarkers could potentially predict individual patient's response to treatment.

Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.

Non-biologic immunosuppressive drugs are crucial for treating autoimmune and chronic inflammatory skin diseases.

New treatments for non-small cell lung cancer are being tested, with some already in use, focusing on immune response and targeting cancer cells, but side effects vary.

Cultured dermal papilla cells can regenerate hair follicles and sustain hair growth.

EGF controls hair growth by regulating hair follicles' growth phases.

HS patients rarely see dermatologists, often get opiates, and need better care.

Treating psoriasis on the scalp, nails, and skin folds is challenging, often requiring systemic treatments for severe cases, with some success in topical and biologic treatments.

Psoriasis patients are willing to pay less than the cost of biologic treatments for remission and don't expect complete or long-term symptom clearance.

Psoriasis increases annual healthcare costs by $4,044 per patient, with biologic treatments costing significantly more than phototherapy.

Lupus affects the body and skin, causing joint pain and skin issues that can be treated with steroids and antimalarial drugs.

COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.

Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.

Dupilumab for eczema may cause hair loss.

Patients with chronic skin conditions on systemic treatments did not have worse COVID-19 outcomes and could resume their treatments after recovery.

The document concludes that treating tough skin disease in lupus involves sun protection, steroids, antimalarials, and various other therapies chosen based on individual risks and benefits.

Immune cells affect hair growth and could lead to new hair loss treatments.

New treatments for hair loss are showing promise due to better understanding of genetics and the immune system.

Cell therapy shows promise for treating severe psoriasis but needs more research to confirm safety and effectiveness.

A young woman had a rare skin reaction to a medication for her joint disease, and a combination therapy improved her condition.

Some treatments can help hair regrowth in alopecia areata, but none offer a cure, and effectiveness varies.

Denosumab treatment for osteoporosis can cause hair loss.

New treatments for skin conditions in children include a preferred drug for birthmark reduction, proactive creams for eczema and vitiligo, a safe psoriasis medication, and special tissues and socks for eczema and fungal infections.

Some skin medications are safe for pregnant women, but others pose risks or should not be used.

The document concludes that proper treatment and management of plaque psoriasis in adolescents can improve their quality of life.

Some drugs, especially biologics, can cause skin reactions that look like other skin diseases, and stopping the drug usually helps clear up these reactions.

Denosumab, a bone loss treatment, may cause hair loss and skin reactions due to immune system effects.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.

The index to ring finger ratio may indicate disease severity in female ankylosing spondylitis patients, but not in males.